2. Signaling Pathways
  3. Anti-infection
  4. Parasite
  5. Leishmania Isoform

Leishmania

Members of the Leishmania genus are obligate, intracellular vector-borne protozoa which can cause a wide spectrum of disease, ranging from asymptomatic infection to diffuse or localized cutaneous leishmaniasis (CL), visceral leishmaniasis (VL) and mucocutaneous leishmaniasis (MCL). Leishmania spp. are members of the order Kinetoplastida due to the presence of a kinetoplast. Leishmaniasis remains a neglected tropical disease, with approximately 310 million individuals at risk for contracting the infection, 12 million people currently infected, and an annual incidence of 2 million new infections. There are two major forms of the parasite, the extracellular promastigote found in the sand fly and the intracellular amastigote found in vertebrate hosts. While the classic mode of Leishmania transmission is through the bite of an infected sand fly, infection through contaminated needles shared among intravenous drug users, blood transfusion, organ transplantation and vertical transmission have also been documented, albeit rarely.

Leishmania Related Products (82):

Cat. No. Product Name Effect Purity
  • HY-B0221
    Amphotericin B
    		≥98.0%
    Amphotericin B is a polyene antifungal agent against a wide variety of fungal pathogens. It binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death.
  • HY-19567
    PK 11195
    		Inhibitor 99.91%
    PK 11195 (RP 52028) is a ligand of translocator protein (TSPO), which targets Leishmania chemotherapy, with IC50s of 14.2 μM, 8.2 μM, 3.5 μM for L. amazonensis, L. major and L. braziliensis, respectively.
  • HY-19719
    Miransertib
    		Inhibitor 99.32%
    Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research. Miransertib is effective against Leishmania.
  • HY-B0537
    Pentamidine
    		Inhibitor
    Pentamidine (MP-601205) is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine inhibits parasite Leishmania infantum with an IC50 of 2.5 μM. Pentamidine is a potent and selective protein tyrosine phosphatases (PTPases) and phosphatase of regenerating liver (PRL) inhibitor. Pentamidine has the potential for Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia treatment. Antitumor and antibacterial activities.
  • HY-B0537B
    Pentamidine isethionate
    		Inhibitor 99.95%
    Pentamidine isethionate (MP-601205 isethionate) is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine isethionate inhibits parasite Leishmania infantum with an IC50 of 2.5 μM. Pentamidine isethionate is a potent and selective protein tyrosine phosphatases (PTPases) and phosphatase of regenerating liver (PRL) inhibitor. Pentamidine isethionate has the potential for Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia treatment. Antitumor and antibacterial activities.
  • HY-B1509A
    Trypaflavin
    		Inhibitor
    Trypaflavin is an acridine compound and antimalarial agent. Trypaflavin invades germ cells. Trypaflavin induces aberrations in unfertilized oocytes. Trypaflavin increases the frequency of chromosomal aberrations. Trypaflavin shows weak mutagenicity. Trypaflavin is highly toxic to Leishmania, causing immediate lysis of the leptomonads.
  • HY-N17550
    25-Hydroperoxycycloart-23-en-3β-ol
    		Inhibitor
    25-Hydroperoxycycloart-23-en-3β-ol is an anticancer, antibacterial, and antimalarial agent. 25-Hydroperoxycycloart-23-en-3β-ol can be isolated from Blepharodon nitidum. 25-Hydroperoxycycloart-23-en-3β-ol exhibits anti-Mycobacterium tuberculosis and antileishmanial activities. 25-Hydroperoxycycloart-23-en-3β-ol shows significant cytotoxic activity against a panel of tumor cell lines (large cell lung cancer, melanoma, colon adenocarcinoma, chronic myelogenous leukemia).
  • HY-W663179
    DNDI-VL-2098
    		Inhibitor
    DNDI-VL-2098 is an orally active antileishmanial agent. DNDI-VL-2098 exhibits high permeability, in vitro metabolic stability, and selective inhibition of CYP2C19 (IC50=0.47 μM). DNDI-VL-2098 does not affect the activities of other major CYP enzymes (CYP1A2, CYP2C9, CYP2D6 and CYP3A4) at concentrations up to 12.5 μM. It shows favorable pharmacokinetic properties in multiple animal models including mice, hamsters, rats and dogs. DNDI-VL-2098 is characterized by moderate to high plasma protein binding and can be used for the research of visceral leishmaniasis.
  • HY-122571
    Retro-2
    		Inhibitor 98.0%
    Retro-2 is a selective inhibitor of retrograde protein trafficking at the endosome-trans-Golgi network interface. Retro-2 is an ebolavirus (EBOV) infection inhibitor with an EC50 of 12.2 μM in HeLa cells. Retro-2 induces cell autophagy.
  • HY-103353
    SID 26681509
    		Inhibitor 99.16%
    SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G.
  • HY-B0621
    Triclabendazole
    		Inhibitor 99.36%
    Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica.
  • HY-N0769
    Isopimpinellin
    		Inhibitor 99.71%
    Isopimpinellin, an orally active compound isolated from Glomerella cingulata. Isopimpinellin blocks DNA adduct formation and skin tumor initiation by 7,12-dimethylbenz[a]anthracene. Isopimpinellin possesses anti-leishmania effect.
  • HY-N2575
    Hypocrellin A
    		Inhibitor 99.73%
    Hypocrellin A is a PKC inhibitor that exerts antidiabetic activity by reversing the effects of high glucose on endothelin (ET-1) expression. Hypocrellin A is also a photosensitizer for photodynamic therapy (PDT) with anticancer, antibacterial and antiviral activities, especially against human immunodeficiency virus (HIV). In addition, Hypocrellin-A also possesses anti-Leishmania activity (IC50=0.27 μg/ml).
  • HY-N6961
    Lapachol
    		Inhibitor 99.49%
    Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity.
  • HY-121241
    Dehydroemetine
    		Inhibitor 99.90%
    Dehydroemetine is an orally active antiparasitic agent. Dehydroemetine can inhibit parasites such as Entamoeba histolytica, and it can also be used in the research of parasitic diseases like visceral leishmaniasis.
  • HY-122818
    BpV(phen) trihydrate
    		Inhibitor 98.0%
    BpV(phen) trihydrate, a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC50s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. BpV(phen) trihydrate inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) trihydrate strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). BpV(phen) trihydrate can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity.
  • HY-N0397
    Harpagide
    		Inhibitor 98.93%
    Harpagide is a class of iridoid glycoside isolated from Scrophularia ningpoensis and has antiparasitic activity, which exhibits good in vitro trypanocidal activities against African trypanosomes (T.b. rhodesiense) with an IC50 of 21 μg/mL. Harpagide exerts significant antileishmanial activity against L. donovani with an IC50 value of 2.0 μg/mL. Harpagide also possess significant anti-inflammatory activities.
  • HY-101397
    Allopurinol riboside
    		Inhibitor 99.71%
    Allopurinol riboside, a metabolite of allopurinol, shows potent activities against parasites.
  • HY-19719A
    Miransertib hydrochloride
    		Inhibitor 99.74%
    Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research. Miransertib hydrochloride is effective against Leishmania.
  • HY-N1453
    Hypocrellin B
    		Inhibitor 99.61%
    Hypocrellin B, a pigment isolated from the fungi Hypocrella bambusae and Shiraia bambusicola, is an apoptosis inducer. Hypocrellin B can be used as a photosensitizer for photodynamic therapy of cancer. Hypocrellin B also has antimicrobial and antileishmanial activities.